Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.
Takashi OguraYoshikazu InoueArata AzumaSakae HommaYasuhiro KondohKatsumi TanakaKaori OchiaiYukihiko SugiyamaToshihiro NukiwaPublished in: Advances in therapy (2023)
ClinicalTrials.gov: NCT02607722; European Union electronic register of Post-Authorisation Studies: EUPAS10891.